School of Public Health, Jilin University, Changchun, Jilin 130021, PR China.
Int J Biol Macromol. 2013 Apr;55:118-22. doi: 10.1016/j.ijbiomac.2012.12.035. Epub 2013 Jan 4.
For the past few years, numerous polysaccharides and polysaccharide-protein complexes have been isolated from plant or animal and used as a promising source of therapeutic agents for diabetes mellitus (DM). In this study, a water-soluble polysaccharide, named as CCPW-1, was extracted and fractioned from the roots of Coptis Chinensis by DEAE Sepharose Fast Flow anion-exchange and Sephadex G-100 column chromatography. The determination of the monosaccharide composition in CCPW-1 with gas chromatography (GC) showed that CCPW-1 was composed of glucose (54.8%), arabinose (22.3%), xylose (11.5%), galactose (7.6%) and galacturonic acid (3.8%). Diabetic mice induced by high-fat diet (HFD) with streptozotocin (STZ) were administered CCPW-1 (100, 50, 25 mg/kg b.w.). Effects of CCPW-1 on bodyweight, fasting blood glucose (FBG), oral glucose tolerance test (OGTT), fasting serum insulin (FINS), total glycerin (TG), total cholesterol (TC), super oxygen dehydrogenises (SOD), catalase (CAT) and methane dicarboxylic aldehyde (MDA) were investigated. CCPW-1 could improve the bodyweight, reduce the content of FBG and enhance FINS level. Meanwhile, CCPW-1 significantly suppressed the rise in blood glucose after 30 min in OGTT. TG and TC levels of diabetic mice also decreased after CCPW-1 treatment. Furthermore, CCPW-1 showed an obvious antioxidant effect through increasing SOD, CAT activities and decreasing MDA content in pancreas. These results indicate that CCPW-1 could be developed to a potent drug used for the treatment of DM in the future.
在过去的几年中，已经从植物或动物中分离出许多多糖和多糖-蛋白质复合物，并将其用作治疗糖尿病（DM）的有前途的药物来源。在这项研究中，从黄连的根部提取并通过 DEAE Sepharose Fast Flow 阴离子交换和 Sephadex G-100 柱层析分离出一种水溶性多糖，命名为 CCPW-1。用气相色谱（GC）测定 CCPW-1 的单糖组成表明，CCPW-1由葡萄糖（54.8％），阿拉伯糖（22.3％），木糖（11.5％），半乳糖（7.6％）和半乳糖醛酸（3.8％）组成。用高脂肪饮食（HFD）加链脲佐菌素（STZ）诱导糖尿病小鼠，并给予 CCPW-1（100、50、25mg/kg b.w.）。研究了 CCPW-1 对体重，空腹血糖（FBG），口服葡萄糖耐量试验（OGTT），空腹血清胰岛素（FINS），甘油三酸酯（TG），总胆固醇（TC），超氧物歧化酶（SOD），过氧化氢酶（CAT）和甲烷二羧酸醛（MDA）的影响。 CCPW-1可以增加体重，降低 FBG 含量并提高 FINS 水平。同时，CCPW-1 可显著抑制 OGTT 后 30 分钟血糖升高。 CCPW-1 治疗后糖尿病小鼠的 TG 和 TC 水平也降低。此外，CCPW-1 通过增加胰腺中的 SOD，CAT 活性和降低 MDA 含量显示出明显的抗氧化作用。这些结果表明，CCPW-1 将来可能被开发为治疗 DM 的有效药物。
